How does DSIP (Intranasal)'s half-life affect dosing?

DSIP (Intranasal) has a plasma half-life of Rapid CNS uptake via olfactory route, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1 spray before sleep dosing at 100-300 mcg per dose explains the typical onset timeline for scheduling and cycle endpoints.

What is the regulatory status of DSIP (Intranasal)?

DSIP (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What does DSIP (Intranasal) stack well with?

For protocol / scheduling / cycling protocols, DSIP (Intranasal) pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from DSIP (Intranasal)'s primary mechanism (Same DSIP molecule delivered intranasally), producing additive or synergistic effects rather than receptor competition.

How long until I see results from DSIP (Intranasal)?

Acute effects from DSIP (Intranasal) appear within the first week for downstream physiological adaptation. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ DSIP (Intranasal)

DSIP (Intranasal)

Protocol

Scheduling DSIP (Intranasal) alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. Intranasal DSIP for direct CNS delivery via the olfactory pathway — bypasses systemic circulation and acts on sleep architecture faster than subcutaneous. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Daily TimingMulti-Peptide TimingStack SchedulingStorage During CycleTravel Considerations

Key Takeaways

Scheduling lens: DSIP (Intranasal)'s Rapid CNS uptake via olfactory route half-life via intranasal places it in the daily-dosing bucket.
Mechanism: Same DSIP molecule delivered intranasally.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for DSIP (Intranasal).

Cycle length and off-cycle planning

Standard DSIP (Intranasal) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any DSIP (Intranasal) protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most DSIP (Intranasal) schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

DSIP (Intranasal) with a Rapid CNS uptake via olfactory route half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1 spray before sleep, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Weekly Timing

For weekly timing scheduling, DSIP (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Multi-Peptide Timing

Schedule design for DSIP (Intranasal) in multi-peptide timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Travel Considerations

The most-asked scheduling question for DSIP (Intranasal) in travel considerations is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Pulse Strategies

For pulse strategies scheduling, DSIP (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	60-300 mcg	4–6 weeks initial cycle
Protocol focus	Intranasal	100-300 mcg	1 spray before sleep
Maintenance phase	Intranasal	70-300 mcg	Ongoing with periodic pauses

Dose timing for DSIP (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

DSIP (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with DSIP (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
DSIP (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with DSIP (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
DSIP (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with DSIP (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
DSIP (Intranasal) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with DSIP (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical

Excellent tolerability. Mild nasal irritation possible.

Lens-specific safety considerations for protocol / scheduling / cycling use of DSIP (Intranasal): Excellent tolerability. Mild nasal irritation possible. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

DSIP (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
DSIP (Intranasal)	Neuropeptide (sleep, intranasal)	Rapid CNS uptake via olfactory route	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Daily timing for DSIP (Intranasal)?

Pragmatic timing depends on pharmacokinetics: single daily dose for moderate half-life. Consistent timing matters more than the absolute clock time of any single dose.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

When to integrate DSIP (Intranasal) into an existing stack?

Add one new compound at a time, with at least 2 weeks of isolated dosing to establish individual response, before layering additional compounds. This approach prevents stack complexity from masking individual contributions and makes troubleshooting tractable.

How do I schedule DSIP (Intranasal) alongside my existing stack?

DSIP (Intranasal)'s schedule is built around its Rapid CNS uptake via olfactory route pharmacokinetics and 1 spray before sleep dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

Is DSIP (Intranasal) safe during pregnancy or breastfeeding?

DSIP (Intranasal), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a DSIP (Intranasal) Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified DSIP (Intranasal) and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: Rapid CNS uptake via olfactory route
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for DSIP (Intranasal)

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised